Feuerstein's Biotech Mailbag
Welcome to the first "biotech mailbag" column. I get a lot of great reader email and feedback, which I try hard to answer directly. But often, there are questions asked or issues raised that could benefit a wider audience.
So consider this new regular column -- weekly, I hope, so keep the email flowing -- a chance to ask me questions about biotech or take me to task for something I wrote. I'll pick the best of the mail and address it here. Now, off to the mailbag.Elemer Piros, a research analyst at Rodman & Renshaw, is more bullish on Neurochem(NRMX Quote) and its Alzheimer's drug Alzhemed than I was in my column this week. While he agrees that the ongoing Alzhemed phase III study is high-risk, he is more optimistic that results will be positive. Specifically, Piros says I neglected an issue with the study that girds his confidence. Piros writes that my column failed to "observe that these patients were on memory enhancers (80% on Aricept) on average for 20 months before they entered this 18-month study. You ignore the possibility that most of these patients were probably declining when they entered the study, and fail to reconcile this with the observation that 36% of the total (latest blinded analysis) has improved on average at the end of the 18 month experiment." (Piros has a market outperform rating on Neurochem, and his firm has done banking for the company in the past 12 months.)
- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,441.12 | 1,109.18 | 2,206.91 | 35.96 |
Oil *
73.55
|
|
DOWN
10.88
|
UP
1.25
|
UP
5.86
|
DOWN
0.07
|
10 Yr
3.60%
SPDR Gold
111.59
|
|
-0.10%
|
+0.11%
|
+0.27%
|
-0.19%
|
Data delayed 20 minutes |














